A recent review explored the intricate relationship between inflammatory bowel disease (IBD) and depressive disorders (DDs), revealing that some IBD patients may experience fewer relapses and diminished corticosteroid reliance with antidepressant treatment. However, findings are limited and mixed, indicating certain biologics, such as ustekinumab and vedolizumab, can trigger depressive symptoms even in those without preexisting psychiatric conditions. The review discusses shared pathophysiological mechanisms and emphasizes the need for a multidisciplinary approach to patient care.

Source: Journal of Clinical Medicine